Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment – Data Using a Blind, Randomized, Clinical Study
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Objectives: In previous studies, around half of all hypothyroid patients preferred levo-thyroxine (L-T4) + levo-triiodothyronine (L-T3) combination therapy, 25% preferred T4, and 25% had no preference. The reason for this is yet to be explored. Methods: A total of 45 overtly autoimmune, hypothyroid patients – now euthyroid on ≥6 months’ L-T4 therapy – participated in a prospective, double-blind, cross-over study. The patients were randomized into 2 groups of either 3 continuous months’ L-T4 therapy followed by 3 months’ combination therapy or vice versa. In all periods, 50 μg L-T4 was blindly replaced by either (identical) 50 μg L-T4 or by 20 μg T3. L-T4 was hereafter adjusted to obtain normal serum TSH values. We investigated 3 single nucleotide polymorphisms (SNPs) on the type II iodothyronine deiodinase (DIO2) gene (rs225014 (Thr92Ala), rs225015, and rs12885300 (ORFa-Gly3Asp)) and 1 SNP on the cellular membrane transport-facilitating monocarboxylate transporter (MCT10) gene (rs17606253), and asked in which of the 2 treatment periods patients felt better (i.e., which treatment was preferred). Results: 27 out of 45 patients (60%) preferred the combination therapy. Two polymorphisms (rs225014 (DIO2, Thr92Ala) and rs17606253 (MCT10)) were combined yielding 3 groups: none vs. 1 of 2 vs. both SNPs present, and 42 vs. 63 vs. 100% of our patients in the 3 groups preferred the combined treatment (Jongheere-Terpstra trend test, p = 0.009). Conclusion: The present study indicates that the combination of polymorphisms in DIO2 (rs225014) and MCT10 (rs17606253) enhances hypothyroid patients’ preference for L-T4 + L-T3 replacement therapy. In the future, combination therapy may be restricted or may be even recommended to individuals harbouring certain polymorphisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using stored samples from one of the combination therapy trials from 2009 (23), a 2017 analysis showed that patients with either the monocarboxylate transporter (MCT)10 polymorphism or both the MCT10 and Thr92Ala polymorphism preferred combination therapy (p-values 0.018 and 0.009, respectively) (24).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [24]
In the citing paper
“For instance, individuals with genetic variants in DIO2 (rs225014)183 and MCT10 (rs12885300) 184 have shown preference for combination levothyroxine-liothyronine therapy with a potential additive effect.184”
From Hypothyroidism (2024) · cites this paper as [184]
In the citing paper
“The co-existence of polymorphisms in the iodothyronine deiodinase 2 (DIO2) gene (rs225014=Thr92Ala) and the thyroid hormone transporter gene monocarboxylate transporter 10 (MCT10; rs17606253) significantly enhanced the preference for T4+T3 combination therapy (the preferences in patients with 0, 1, or 2 polymorphisms were 42%, 63%, and 100% respectively) [47].”
From T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity (2021) · cites this paper as [47]
In the citing paper
“However, these studies had limitations due to multiple testing 183 and small sample size.184”
From Hypothyroidism (2024) · cites this paper as [184]
In the citing paper
“However, one involved a small patient cohort ( n = 45) and neither provided robust statistical testing for multiple variants genotyped ( n = 16 and n = 4 SNPs). 52,53”
From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [53]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Wacholder, S., Chanock, S., Garcia-Closas, M., El ghormli, L., & Rothman, N. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh075 · Cited by 1,754
Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
Rodriguez, S., Gaunt, T. R., & Day, I. N. M. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwn359 · Cited by 1,048
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Self-citationPanicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299
Research works printed but not linked: 2
- Medici M, van der Deure WM, Verbiest M, Vermeulen SH, Hansen PS, Kiemeney LA, Hermus AR, Breteler MM, Hofman A, Hegedüs L, Kyvik KO, den Heijer M, Uitterlinden AG, Visser TJ, Peeters RP: A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT4 levels. Eur J Endocrinol 2011;164: 781–788.10.1530/EJE-10-113021367965 · DOI · Paper page
- Rothman KJ, Greenland S: Modern Epidemiology, ed 2. Philadelphia, Lippincott-Raven Publishers, 1988.
Cited by
Deiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Paradigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231
“Retrospective data suggest that patient preference may be linked to a patient’s complement of thyroid hormone metabolism-associated polymorphisms (42,43).”
Groeneweg, S., van Geest, F. S., Peeters, R. P., Heuer, H., & Visser, W. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz008 · Cited by 216
“A more recent study suggested that individuals harboring this variant in combination with 1 of the 3 variants studied in DIO2 (rs225014, rs22501, or rs12885300) may modulate hypothyroid patients’ preference for levothyroxine (L-T4) + liothyronine (L-T3) replacement therapy over L-T4 alone (304).”
BackgroundHashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationPrimary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Taylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Thyroid hormone therapy for hypothyroidism
Biondi, B., & Cooper, D. S. (2019) · Endocrine · doi:10.1007/s12020-019-02023-7 · Cited by 119
Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain
Jo, S., Fonseca, T. L., Bocco, B. M. L. C., Fernandes, G. W., McAninch, E. A., Bolin, A. P., Da Conceição, R. R., Werneck-de-Castro, J. P., Ignacio, D. L., Egri, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123176 · Cited by 107
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationIndividualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?
Calissendorff, J., & Falhammar, H. (2020) · Medicina · doi:10.3390/medicina56010040 · Cited by 89
“In a small Danish study, 27 out of 45 patients with gene polymorphism in rs225014 (DIO2, Thr92Ala) and / or polymorphism in the thyroid hormone transporter rs17606253 (MCT10) ( n = 26) preferred the combined treatment more often than patients without such polymorphisms [76].”
Perros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Dayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
Millan-Alanis, J. M., González-González, J. G., Flores-Rodríguez, A., Singh Ospina, N., Maraka, S., Moreno-Peña, P. J., Brito, J. P., González-Velázquez, C., & Rodríguez-Gutiérrez, R. (2021) · Thyroid® · doi:10.1089/thy.2021.0270 · Cited by 60
“The presence of this polymorphism has been linked to psychological impairment among patients on monotherapy, better response to combined therapy, and higher preferences for it (13,15).”
Pathophysiological relevance of deiodinase polymorphism
Bianco, A. C., & Kim, B. S. (2018) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000428 · Cited by 59
Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09691-9 · Cited by 53
“(for the rs225014 polymorphism in DIO2 and the rs17606253 polymorphism in MCT10/SLC16A10) [103].”
BackgroundTHERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect?
Wiersinga, W. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0645 · Cited by 52
The Genetic Basis of Thyroid Function: Novel Findings and New Approaches
Kuś, A., Chaker, L., Teumer, A., Peeters, R. P., & Medici, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz225 · Cited by 44
“More recently, Carle et al (96) performed a small (N = 45) prospective double-blind randomized clinical trial in which they found that hypothyroid patients harboring combined MCT10-rs17606253 and DIO2-rs225014 variants (P = 0.009), but not DIO2-rs225014 alone (P > 0.05), may prefer LT4/LT3 combination treatment.”
BackgroundInfluentialThe relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Ross, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42
Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics
Jonklaas, J., Tefera, E., & Shara, N. (2018) · Thyroid · doi:10.1089/thy.2018.0325 · Cited by 41
“(27), regarding the consequences of deiodinase polymorphisms or impairment of deiodinase function, albeit mostly in animal studies (28), retrospective or cross-sectional rather than prospective studies (29–31), or small studies (30).”
BackgroundIndividualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Drugs in Context · doi:10.7573/dic.212597 · Cited by 41
Akirov, A., Fazelzad, R., Ezzat, S., Thabane, L., & Sawka, A. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00477 · Cited by 37
“[original publication (18), secondary publication (23)].”
T4 + T3 combination therapy: any progress?
Wiersinga, W. M. (2019) · Endocrine · doi:10.1007/s12020-019-02052-2 · Cited by 35
Ahluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14935 · Cited by 34
“52,53 However, one involved a small patient cohort ( n = 45) and neither provided robust statistical testing for multiple variants genotyped ( n = 16 and n = 4 SNPs).”
BackgroundAxonal T3 uptake and transport can trigger thyroid hormone signaling in the brain
Salas-Lucia, F., Fekete, C., Sinkó, R., Egri, P., Rada, K., Ruska, Y., Gereben, B., & Bianco, A. C. (2023) · eLife · doi:10.7554/elife.82683 · Cited by 33
Critical Approach to Hypothyroid Patients With Persistent Symptoms
Biondi, B., Celi, F. S., & McAninch, E. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad224 · Cited by 34
The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
McAninch, E. A., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00446 · Cited by 24
Patient Experiences and Perceptions Associated with the Use of Desiccated Thyroid Extract
Toloza, F. J. K., Espinoza Suarez, N. R., El Kawkgi, O., Golembiewski, E. H., Ponce, O. J., Yao, L., Maraka, S., Singh Ospina, N. M., & Brito, J. P. (2020) · Medicina · doi:10.3390/medicina56040161 · Cited by 22
“These polymorphisms have been linked in retrospective studies with patients’ self-reported preference with combined thyroid therapy [35,36].”
ResultJonklaas, J., Tefera, E., & Shara, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00031 · Cited by 23
Functional and Symptomatic Individuality in the Response to Levothyroxine Treatment
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00664 · Cited by 22
T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
Wiersinga, W. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.501 · Cited by 21
“org Copyright © 2021 Korean Endocrine Society deiodinase 2 (DIO2) gene (rs225014=Thr92Ala) and the thyroid hormone transporter gene monocarboxylate transporter 10 (MCT10; rs17606253) significantly enhanced the preference for T4+T3 combination therapy (the preferences in patients with 0, 1, or 2 polymorphisms were 42%,…”
BackgroundBrigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Combination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 21
“Individuals with genetic variants in DIO2 (rs225014) (80) and MCT10 (rs12885300) (77) have shown preference for combination LT3:LT4 therapy with an additive effect (77).”
BackgroundPhysiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients
Fröhlich, E., & Wahl, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.587518 · Cited by 20
“Patients with MCT10 (rs17606253) polymorphism, on the other hand, preferred the combination therapy to L-T4 monotherapy (128).”
BackgroundCombination Therapy for Hypothyroidism: Rationale, Therapeutic Goals, and Design
Madan, R., & Celi, F. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00371 · Cited by 18
Clinical significance of type 2 iodothyronine deiodinase polymorphism
Maino, F., Cantara, S., Forleo, R., Pilli, T., & Castagna, M. G. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1523714 · Cited by 17
Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism
Penna, G., Salas-Lucia, F., Ribeiro, M. O., & Bianco, A. C. (2023) · Endocrine · doi:10.1007/s12020-023-03528-y · Cited by 20
“This seems to be particularly true for patients that exhibit residual symptoms while on therapy with LT4 [89], or when an association with the MCT10 SNP rs17606253 was also considered [90].”
Identification of Resistance to Exogenous Thyroxine in Humans
Lacámara, N., Beatriz Lecumberri, S., Barquiel, B., Escribano, A., Casado, I. G., Álvarez‐Escolá, C., Blanquer, F. A., Morales, F., Alfayate, R., Bernal-Soriano, M. C., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0825 · Cited by 17
Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review
Razvi, S., Mrabeti, S., & Luster, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0205 · Cited by 15
Wang, X., Chen, K., Zhang, C., Wang, H., Li, J., Wang, C., Teng, W., Shan, Z., & Lai, Y. (2021) · BioMed Research International · doi:10.1155/2021/9914009 · Cited by 13
Variants in MCT10 protein do not affect FT3 levels in athyreotic patients
Cantara, S., Ricci, C., Maino, F., Marzocchi, C., Pacini, F., & Castagna, M. G. (2019) · Endocrine · doi:10.1007/s12020-019-02001-z · Cited by 12
Al-Rasheed, M. M., AlAnzi, A., Alshalhoub, R., Abanmy, N. O., & Bakheet, D. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.05.005 · Cited by 11
“Specifically, the DIO2 gene has been associated with diseases such autoimmune hypothyroidism disease (Carle et al., 2017), maternal thyroid status (He et al.”
Zhang, H., Tong, W., Zeng, W., Luo, H., Zhang, L., Feng, J., Xiao, Y., & Wang, G. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627787 · Cited by 19
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
“60,61 Only one study investigated whether improvement in QoL depended on the presence of this gene variant, but no such association was demonstrated.”
New insights on thyroid hormone and the brain
Bernal, J. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2017.12.001 · Cited by 12
Cognitive function in hypothyroidism: what is that deiodinase again?
Hernández, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125203 · Cited by 10
Stanculescu, D., Larsson, L., & Bergquist, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.672370 · Cited by 10
Heim, M., Nixon, I. J., Emmerson, E., & Callanan, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.997288 · Cited by 13
“Indeed, studies have indicated that this particular SNP is associated with a significantly enhanced response to combination therapy and impaired baseline psychological well-being when on T4 monotherapy (139, 140).”
BackgroundLarsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Grøenvold, M., Bjørner, J. B., Hegedűs, L. D., Watt, T., & Bonnema, S. J. (2023) · Thyroid Research · doi:10.1186/s13044-023-00178-0 · Cited by 12
Role of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism
Jonklaas, J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.003 · Cited by 10
Tissue sensitivity to thyroid hormones may change over time
Radetti, G., Rigon, F., Salvatoni, A., Campi, I., Filippis, T. D., Cirello, V., Longhi, S., Guizzardi, F., Bonomi, M., & Persani, L. (2022) · European Thyroid Journal · doi:10.1530/etj-21-0054 · Cited by 7
Nice guideline on thyroid disease: where does it take us with liothyronine?
Leese, G. (2020) · Thyroid Research · doi:10.1186/s13044-020-00081-y · Cited by 7
Jensen, C. Z., Isaksen, J. L., Ahlberg, G., OLESEN, M. S., Nygaard, B., Ellervik, C., & Kanters, J. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad556 · Cited by 8
Self-citationKang, Y. M., Koo, B. S., Yi, H., Kim, J. T., Park, B., Lee, J. H., Shong, M., & Kang, Y. E. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.292 · Cited by 7
“The combination of polymorphisms in DIO2 (rs225014) and monocarboxylate transporter 10 (MCT10) (rs17606253) enhances hypothyroid patients’ preference for L-T4 + L-T3 replacement therapy [22], and patients with hypothyroidism with DIO2 polymorphism are also known to have improved well-being in response to combination t…”
BackgroundMethodInfluentialEnhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?
Perros, P., & Hegedűs, L. D. (2022) · Intern J Endocrinol Metab · doi:10.5812/ijem-127230 · Cited by 6
“A, improved thyroid hormone efficacy by overcoming “defects” in thyroid hormone transport or metabolism (71, 72); B, placebo effect (2); C, patient perception of superior clinical care delivered by physicians who prescribe excess thyroid hormones (16, 58); D, enhanced well-being associated with thyrotoxicosis.”
BackgroundJensen, C. Z., la Cour, J. L., Watt, T., Kanters, J. K., Poulsen, H. E., Faber, J. O., Ellervik, C., & Nygaard, B. (2022) · Thyroid · doi:10.1089/thy.2022.0335 · Cited by 5
Self-citationOta, T., Mori, J., Kawabe, Y., Morimoto, H., Fukuhara, S., Kodo, K., Sugimoto, S., Kosaka, K., Nakajima, H., & Hosoi, H. (2022) · Children · doi:10.3390/children9101421 · Cited by 5
Levothyroxine Monotherapy: What Works Better for the Individual With Hypothyroidism?
Hennessey, J. V. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.013 · Cited by 4
Stevens, E. W., & Leung, A. M. (2018) · Clinical Thyroidology · doi:10.1089/ct.2018;30.175-178 · Cited by 3
Targeting the right population for T3 + T4 combined therapy: where are we now and where to next?
Porcelli, T., & Salvatore, D. (2020) · Endocrine · doi:10.1007/s12020-020-02391-5 · Cited by 3
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.90685 · Cited by 9
“Recent studies and consensus documents highlight the role of genetic polymorphisms (e.g., DIO2 Thr92Ala, MCT10 variants), variable deiodinase activity, and patient-reported outcomes in shaping individual responses to therapy [6,24,44,45].”
Genetics of Thyroid Function: Relevance for Biology and Disease Management
Sterenborg, R. B. T. M., Peeters, R. P., Visser, W. E., Kuś, A., Smit, J. W. A., Teumer, A., & Medici, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf491 · Cited by 3
Liothyronine use in primary hypothyroidism — current concepts
Concepción‐Zavaleta, M. J., Ildefonso-Najarro, S. P., Paz‐Ibarra, J., Fernández-Dávila, F. V., Condori, D. C. D.-G., Rivera-Fabián, K., Herrera-Cabezas, R. G., & Urteaga, L. A. C. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0093 · Cited by 4
“Individuals with genetic variants in D2 [42] and the thyroid hormone transporter protein MCT10 [43] have shown a preference for combined LT4 + LT3 therapy with an additive effect.”
Caron, P. J. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.05.005 · Cited by 2
Tsanava, I. A., Bulgakova, S. V., & Melikova, A. V. (2021) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2021-66-5-261-265 · Cited by 1
Chen, J., Lin, Z., Luo, Y., Tang, H., Chen, F., Liu, P., & Huang, Y. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02085-x · Cited by 1
“For these patients, T3 and T4 combination therapy may contribute to alleviate hypothyroidism symptoms, such as fatigue and malaise, improve quality of life, and enhance adherence to TSH suppression therapy [25, 26].”
Concepción‐Zavaleta, M. J., Cruz, J. P. V.-D. L., Fuentes‐Mendoza, J. M., Urteaga, L. A. C., Flórez, C. D. A., Basurto-Ayala, A., & Paz‐Ibarra, J. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2663365 · Cited by 1
“Supporting this concept, a Danish study demonstrated that polymorphisms in DIO2 and MCT10 genes were associated with patient preference for combination LT4 + LT3 therapy, suggesting a role for genotype-guided treatment strategies (Carlé et al., 2017).”
Bartalena, L., Gallo, D., Piantanida, E., & Tanda, M. L. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2676876 · Cited by 1
“According to a small Danish study, carriers of the type 2 DIO Thr92Ala and monocarboxylate transporter (MCT)10 polymorphisms more frequently preferred the combined treat-ment [157].”
Schmidt, B., Asaad, S., Mavarani, L., Stang, A., Chillon, T. S., Minich, W. B., Renko, K., Brenner, T., Schöler, L., Dittmer, U., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104273 · Cited by 1
Nygaard, B. (2022) · doi:10.1093/med/9780198870197.003.0072 · Cited by 1
Self-citationAzizi, F., Moeini, A. S. H., Mehran, L., Masoumi, S., Abdi, H., Foroutan, S. M., Saghafinia, A. E., & Amouzegar, A. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100395 · Cited by 4
Symptoms in Patients Being Treated for Hypothyroidism: New Data in a Continuing Controversy
Mammen, J. S., & Cooper, D. S. (2023) · Thyroid · doi:10.1089/thy.2023.0307 · Cited by 2
“13 Thus, in a subgroup of patients it may be appropriate to try balanced combination therapy that continues to target a reference range TSH, as recently discussed by the American Thyroid Association.”
Mang, N., Tămaş, L., Mărginean, O., Marian, C., Ursoniu, S., & Anghel, A. (2019) · Revista română de medicină de laborator · doi:10.2478/rrlm-2019-0012
“In hypothyroidism almost 12% of all patients treated with levothyroxine will achieve normal serum levels of TSH (euthyroidism) but continue to have residual symptoms of hypothyroidism, such as psychological and metabolic effects (18,19).”
BackgroundRodríguez-Cortés, Y. M., Chávez, A. A., Fabila, M. G., Morales, S. J., Pérez-Amado, C. J., & Zerón, H. M. (2019) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-019-00084-3
Schilddrüsenerkrankungen in der Peri- und Postmenopause
Mondorf, A. W., Meyer, G., & Bojunga, J. (2019) · Der Gynäkologe · doi:10.1007/s00129-019-4490-y
Derwahl, M. (2019) · Der Nuklearmediziner · doi:10.1055/a-0916-6665
“[5] Carle A, Faber J, Steffensen R et al.”
BackgroundSchilddrüsenerkrankungen in der Peri- und Postmenopause
Mondorf, A. W., Meyer, G., & Bojunga, J. (2021) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-021-00186-z
Time to refresh thinking on the terminology and management of hypothyroidism?
Leese, G., & Soto‐Pedre, E. (2021) · Clinical Endocrinology · doi:10.1111/cen.14485
Pasión e identidad: el problema del conocimiento en el "De anima" de Aristóteles
Martín, J. I. A. S. (1999) · Dialnet (Universidad de la Rioja)
Therapeutic use of triiodothyronine in hypothyroidism: Current status and the road ahead
Das, S. (2023) · Journal of Integrative Medicine and Research · doi:10.4103/jimr.jimr_7_23
Terapia dell’ipotiroidismo primitivo: un ormone o due ormoni?
Brigante, G., Ceccarini, G., Porcelli, T., Santini, F., Salvatore, D., Simoni, M., & Bartalena, L. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01429-4
“Dallo stesso studio emerge che anche i soggetti porta-tori della variante rs17606253 del gene codificante per il tra-sportatore del monocarbossilato (MCT)-10 preferirebbero il trattamento con aggiunta della L-T3 [22].”
Perros, P. (2024) · Copernicus books · doi:10.1007/978-3-031-58287-5_5
Hoermann, R., & Dietrich, J. W. (2025) · Springer eBooks · doi:10.1007/978-981-96-3682-2_11
Hoermann, R., & Dietrich, J. W. (2025) · Springer eBooks · doi:10.1007/978-981-96-3682-2_10
Precision Thyroid Hormone Therapy for Hypothyroidism
Bianco, A. C., & Beltrão, F. E. D. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_24
Larsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Groenvold, M., Bjorner, J. B., Hegedüs, L., Watt, T., & Bonnema, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.26614339
Bing, Y., Liu, Y., Zhou, Z., Li, Y. W., Han, Y., Meng, G., & Jiang, Y. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261444838
“37,38 These findings suggest that systemic euthyroidism does not necessarily equate to optimal tissue-level TH signaling.”
Hypothyroidism Management: Beyond TSH: A Clinical Review
Mazza, A. D., & Dehn, B. (2026) · Clinical Journal for Nurse Practitioners in Women s Health · doi:10.1891/cjnpwh-2025-0063
Metadata
- Authors
- Carlé, A., Faber, J., Steffensen, R., Laurberg, P., & Nygaard, B.
- Affiliations
- Aalborg University Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Carlé, Allan
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2017-04-24
- Volume
- 6
- Issue
- 3
- Pages
- 143-151
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC5527224
- OpenAlex
- W2610020281
- Cited by
- 93
- References
- 48
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 10 · 2021: 14 · 2020: 11 · 2019: 17 · 2018: 9 · 2017: 1
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- hypothyroidism, combination thyroid hormone therapy, levothyroxine, patient treatment preferences, single nucleotide polymorphisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.